Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $60.89 Consensus Target Price from Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has received an average rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $60.89.

A number of equities research analysts have commented on HALO shares. JMP Securities increased their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company reduced their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $57.10 on Friday. Halozyme Therapeutics has a twelve month low of $34.36 and a twelve month high of $65.53. The company has a market capitalization of $7.26 billion, a P/E ratio of 18.91, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a 50-day moving average price of $51.55 and a two-hundred day moving average price of $54.41.

Insider Transactions at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

Several institutional investors have recently bought and sold shares of HALO. Heck Capital Advisors LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter valued at $29,000. Smartleaf Asset Management LLC lifted its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 197 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares during the period. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics in the third quarter valued at about $57,000. Finally, FSC Wealth Advisors LLC purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $65,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.